Avadel Pharmaceuticals plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AVDL Nasdaq 2830 www.avadel.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement - Jan 22nd, 2025 1:00 pm
Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Jan 9th, 2025 7:01 am
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch - Jan 8th, 2025 9:15 pm
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 6th, 2025 9:05 pm
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - Jan 3rd, 2025 1:00 pm
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock - Dec 12th, 2024 10:06 am
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy - Dec 11th, 2024 1:00 pm
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Nov 14th, 2024 10:16 am
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Nov 13th, 2024 1:00 pm
Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ... - Nov 13th, 2024 7:09 am
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 12:00 pm
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 - Nov 4th, 2024 1:00 pm
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Nov 1st, 2024 3:41 pm
Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term - Nov 1st, 2024 12:05 pm
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - Oct 31st, 2024 11:00 am
Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances - Oct 24th, 2024 12:00 pm
Avadel wins FDA approval for narcolepsy drug Lumryz in children - Oct 18th, 2024 8:34 pm
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz - Oct 18th, 2024 1:38 pm
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy - Oct 17th, 2024 1:41 pm
Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Oct 9th, 2024 9:36 pm